Search company, investor...

WaveTec Vision

wavetecvision.com

Founded Year

1997

Stage

Acquired | Acquired

Total Raised

$67.5M

About WaveTec Vision

WaveTec Vision specializes in intraoperative wavefront guidance technology for cataract surgeons, providing on-demand information that increases the precision of cataract surgery so patients achieve their best possible vision. Based in Aliso Viejo, California, USA, WaveTec manufactures the proprietary ORA System that delivers optimal cataract surgery results for demanding patients and the skilled surgeons who serve them.

Headquarters Location

66 Argonaut Suite 160

Aliso Viejo, California, 92656,

United States

949-273-5970

Missing: WaveTec Vision's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: WaveTec Vision's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing WaveTec Vision

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

WaveTec Vision is included in 1 Expert Collection, including Clinical Encounter Tech.

C

Clinical Encounter Tech

625 items

WaveTec Vision Patents

WaveTec Vision has filed 26 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/9/2014

4/18/2017

Ophthalmology, Eye surgery, Vision, Corrective lenses, Fiber optics

Grant

Application Date

10/9/2014

Grant Date

4/18/2017

Title

Related Topics

Ophthalmology, Eye surgery, Vision, Corrective lenses, Fiber optics

Status

Grant

Latest WaveTec Vision News

Allegro Ophthalmics Names Scott Cooper as Chief Financial Officer and Vice President of Business Development and Mohamed Genead MD as Executive Medical Director

Oct 21, 2015

Laurence J. N. Cooper now ZIOPHARM CEO -- Genead, an Ophthalmologist and Retina Specialist, Brings Proven Record in Ophthalmic Drug Development Allegro Ophthalmics, LLC, a biotechnology company focused on the development of therapies to treat vitreoretinal diseases, today announced that Scott Cooper has joined the company as Chief Financial Officer (CFO) and Vice President of Business Development, and that Mohamed Genead, MD, has been named Executive Medical Director. “We are delighted to welcome Scott and Mohamed to Allegro,” says Hampar Karageozian, MSc, MBA, Co-Founder and Chief Executive Officer, Allegro Ophthalmics. “Scott’s incredibly successful record at WaveTec and IntraLase demonstrates how exceptionally well-prepared he is to lead Allegro’s finance and business development functions. Mohamed’s exceptional 15 years of clinical research and drug development experience in retina will serve Allegro well as we move our lead investigational drug Luminate® through multiple clinical trials for several vitreoretinal indications. With these two new additions, Allegro is poised for much growth and success.” A veteran finance executive, Mr. Cooper has spent nearly his entire career, which spans more than 25 years, in financial operations and accounting at numerous medical device and high-tech companies, and has worked for ophthalmic medical device companies for the last 11 years. Most recently, Mr. Cooper served as the CFO of WaveTec Vision Systems, Inc., joining the company in 2007. He helped guide the company through the development and commercialization stages of its intraoperative aberrometer (ORA) that ultimately led to the recent sale of WaveTec to Alcon, a division of Novartis. Prior to WaveTec, Mr. Cooper was Corporate Controller at IntraLase Corp., helping to take it from a private company through IPO to the ultimate sale of the company to Advanced Medical Optics. “This is a very exciting time for Allegro,” says Mr. Cooper. “Should Luminate continue to show the same results in its clinical program as it has in earlier stages, Allegro is uniquely positioned to make a significant contribution to the prevention of vision loss from retinal disease. I am excited to join the Allegro team and look forward to supporting the company’s strategic vision and growth objectives.” In his role at Allegro, Dr. Genead will work to drive the Luminate platforms into further clinical development as he works closely with the R&D, manufacturing, and product development teams, and will be responsible for running the U.S. and international clinical studies of Luminate in diabetic macular edema (DME) and posterior vitreous detachment. Prior to joining Allegro, Dr. Genead was Global Medical Director of Clinical Development in the Ophthalmology/Retina therapeutics area at Allergan, where he was responsible for such tier-1 projects as DARPins for neovascular age-related macular degeneration (AMD) and DME, and Brimonidine DDS implants for geographic atrophy. In addition, he served as subject matter and translational medicine expert on retina therapeutics and discovery. Before joining Allergan, Dr. Genead was Clinical Professor of Ophthalmology, Department of Ophthalmology and Visual Sciences, at the University of Illinois in Chicago. Dr. Genead sits on the board of several organizations and scientific advisory boards, and is the author of more than 40 peer-reviewed papers. “I’m looking forward to working with the Allegro team to advance Luminate’s clinical program across multiple indications and phases. There is a great need for novel, alternative therapies to treat a host of vitreoretinal diseases,” says Dr. Genead. “Based on the clinical results to date, Luminate has the potential to be a valuable treatment option to millions of people who are at risk of vision loss and blindness.” About Luminate Luminate, a first-in-class integrin peptide therapy, treats vitreoretinal diseases by targeting integrin receptors involved in cell signaling and regulation and in the construction of new and aberrant blood vessels. By utilizing two mechanisms of action (vitreolysis and anti-angiogenesis), Luminate has been shown in clinical studies to date to effectively regress and inhibit new blood vessel formation, as well as reduce vascular leakage to maintain and restore vision. Currently in Phase 2 clinical trials for multiple indications, including diabetic macular edema (DME) and non-proliferative diabetic retinopathy (NPDR), Luminate is an investigational drug not approved by the FDA for commercial sale in the U.S. Allegro maintains commercial rights to Luminate in all territories outside of Japan, Korea and China. About Allegro Ophthalmics, LLC With more than 100 years of combined experience in ophthalmic drug discovery, development and manufacturing, Allegro Ophthalmics, LLC, is working to establish integrin peptide therapy as the next-generation pharmaceutical category for the treatment of vitreoretinal diseases. Allegro’s lead investigational drug, Luminate, is currently in Phase 2 studies and has the potential to significantly reduce the current burden of intravitreal injections and to be a viable option for patients with diabetic macular edema, diabetic retinopathy, wet age-related macular degeneration, and vitreomacular traction. By quickly, safely and cost-effectively bringing to market new and improved treatment options for leading causes of blindness, Allegro is committed to offering patients an improved quality of life sustained by self-sufficient, functional vision. For more information, visit www.allegroeye.com . Luminate® is a registered trademark of Allegro Ophthalmics, LLC. View source version on businesswire.com: http://www.businesswire.com/news/home/20151021005320/en/ MEDIA:

WaveTec Vision Frequently Asked Questions (FAQ)

  • When was WaveTec Vision founded?

    WaveTec Vision was founded in 1997.

  • Where is WaveTec Vision's headquarters?

    WaveTec Vision's headquarters is located at 66 Argonaut, Aliso Viejo.

  • What is WaveTec Vision's latest funding round?

    WaveTec Vision's latest funding round is Acquired.

  • How much did WaveTec Vision raise?

    WaveTec Vision raised a total of $67.5M.

  • Who are the investors of WaveTec Vision?

    Investors of WaveTec Vision include Alcon, Versant Ventures, De Novo Ventures, Accuitive Medical Ventures, Gund Investment Corporation and 7 more.

  • Who are WaveTec Vision's competitors?

    Competitors of WaveTec Vision include RxSight, TransMedics, Visioneering Technologies, VisionCare Ophthalmic Technologies, Ocular Therapeutix and 10 more.

Compare WaveTec Vision to Competitors

TheraTogs Logo
TheraTogs

TheraTogs, based in Telluride, Colorado, is a medical device company offering orthotic undergarment and strapping systems that give users with sensorimotor impairment modality for improving postural alignment and stability movement skill and precision and joint stability.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

TransMedics Logo
TransMedics

TransMedics offers portable ex-vivo perfusion and assessment of donor organs for transplantation. The company was founded to address the need for organ transplantation. It focuses on transforming organ utilization, improving patient outcomes, and reducing transplant costs throughout the health care system. The platform develops technology for preserving organs used in the treatment of end-stage heart, lung, and liver failure. The company was founded in 1998 and is based in Andover, Massachusetts.

I
IN2BATE

IN2BATE is prepared to enter the emergency medicine market by offering a cricothyroidotomy device. A cricothyroidotomy is an emergency procedure that is performed on patients suffering from an obstructed airway, usually caused by a trauma accident. Thorough market research has allowed for us to create a strategic advantage over the competition by creating a solution for an uncontested market space. The company's target market includes hospitals--specifically emergency departments, ambulance service companies, ambulance supply companies, and emergency response units.

C
C Change Biosciences

C Change Surgical Llc is a medical device company. It had developed the Intratemp Solution Warmer.Introducing IntraTemp, it will take the uncertainty out of surgical fluids. IntraTemp defines the new standard of care in portable controlled-temperature for irrigation and lavage fluids. Instead of warming fluids away from where you are using them, IntraTemp is completely mobile, allowing for a more efficient way to guarantee the correct temperature to your patients. It will reduce risks for your patients and stress for your staff. It puts temperature control where you need it, when you need it. IntraTemp provides temperature data for chartable proof of quality care.

V
Verimetra

Verimetra aims to make medical instruments "smart" and manufacturers miniature thin film sensors used in medical applications that involve very small high end catheters. The Company designs and manufactures sensors using micro-electromechanical systems (MEMS) technology, which is the only method available that produces sensors small enough to be embedded in surgical devices without changing their basic form or function, allowing the company's customers to sell the same products, now "smart", without requiring the surgeon to use a new device. Verimetra aims to make medical devices "smart" by embedding (US Patent 6,494,882) a variety of small sensors at an place on or within the device. Simply stated, the company make "dumb" metal tools "smart". Examples include forceps, grippers, retractors, drills, and other surgical devices. Through the use of Verimetra's products, medical device manufacturers are able to deliver features and functionality that, depending on the medical procedure, improve outcomes, reduce risk and shorten patient recovery times. Verimetra's new product features are also used by manufacturers to strengthen their market position, enter new markets and maintain gross margins. Verimetra aims to give these manufacturers a way to accomplish these goals by adding features at a low cost without product redesign. Furthermore, in many instances, Verimetra's customers' goals will be met by the transformation of a re-usable product (one-time sale) into a smart disposable product (one sale per procedure).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.